Ironwood Pharmaceuticals, Inc. (IRWD) Receives Consensus Recommendation of “Hold” from Analysts

Share on StockTwits

Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) have been assigned a consensus recommendation of “Hold” from the sixteen analysts that are currently covering the stock, Marketbeat.com reports. Nine investment analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $17.35.

IRWD has been the subject of a number of recent analyst reports. BidaskClub downgraded Ironwood Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, December 20th. Zacks Investment Research downgraded Ironwood Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, January 8th. Mizuho raised their target price on Ironwood Pharmaceuticals to $20.00 and gave the company a “buy” rating in a report on Tuesday, January 15th. JPMorgan Chase & Co. raised Ironwood Pharmaceuticals from an “underweight” rating to a “neutral” rating and raised their target price for the company from $11.00 to $13.00 in a report on Thursday, January 24th. Finally, Wood & Company reissued a “buy” rating on shares of Ironwood Pharmaceuticals in a report on Thursday, January 31st.

In other news, insider Mark G. Currie sold 275,000 shares of Ironwood Pharmaceuticals stock in a transaction on Friday, March 8th. The stock was sold at an average price of $13.26, for a total transaction of $3,646,500.00. Following the completion of the transaction, the insider now owns 577,980 shares of the company’s stock, valued at approximately $7,664,014.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Gina Consylman sold 5,677 shares of Ironwood Pharmaceuticals stock in a transaction on Thursday, February 21st. The stock was sold at an average price of $14.31, for a total value of $81,237.87. Following the transaction, the chief financial officer now directly owns 168,543 shares of the company’s stock, valued at approximately $2,411,850.33. The disclosure for this sale can be found here. Insiders have sold a total of 403,872 shares of company stock valued at $5,281,958 in the last ninety days. Corporate insiders own 7.63% of the company’s stock.

Several large investors have recently added to or reduced their stakes in the company. First Manhattan Co. raised its stake in shares of Ironwood Pharmaceuticals by 206.1% during the 1st quarter. First Manhattan Co. now owns 39,564 shares of the biotechnology company’s stock worth $535,000 after buying an additional 26,639 shares during the last quarter. Tibra Equities Europe Ltd acquired a new position in shares of Ironwood Pharmaceuticals during the 1st quarter worth $920,000. Geode Capital Management LLC raised its stake in shares of Ironwood Pharmaceuticals by 6.0% during the 4th quarter. Geode Capital Management LLC now owns 1,658,754 shares of the biotechnology company’s stock worth $17,184,000 after buying an additional 94,453 shares during the last quarter. Norges Bank acquired a new position in shares of Ironwood Pharmaceuticals during the 4th quarter worth $19,568,000. Finally, Dimensional Fund Advisors LP acquired a new position in shares of Ironwood Pharmaceuticals during the 4th quarter worth $252,000. 97.00% of the stock is owned by institutional investors and hedge funds.

Ironwood Pharmaceuticals stock traded down $0.08 during midday trading on Wednesday, reaching $11.40. The company’s stock had a trading volume of 1,057,209 shares, compared to its average volume of 1,491,030. Ironwood Pharmaceuticals has a fifty-two week low of $9.07 and a fifty-two week high of $21.20. The company has a market cap of $1.82 billion, a P/E ratio of -12.00 and a beta of 1.91.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its earnings results on Wednesday, February 13th. The biotechnology company reported ($0.02) EPS for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.15. The business had revenue of $130.70 million during the quarter, compared to analyst estimates of $96.57 million. During the same period last year, the business posted ($0.14) EPS. Ironwood Pharmaceuticals’s revenue was up 38.7% compared to the same quarter last year. On average, equities analysts anticipate that Ironwood Pharmaceuticals will post 0.04 EPS for the current fiscal year.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout in adults under the ZURAMPIC and DUZALLO names.

Recommended Story: What is an Initial Public Offering (IPO)?

Analyst Recommendations for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Sportech  Trading Down 0.3%
Sportech Trading Down 0.3%
Short Interest in Hilltop Holdings Inc.  Expands By 23.8%
Short Interest in Hilltop Holdings Inc. Expands By 23.8%
Aeorema Communications  Trading Down 3.7%
Aeorema Communications Trading Down 3.7%
Hiscox  Reaches New 52-Week High at $1,729.00
Hiscox Reaches New 52-Week High at $1,729.00
Oceanic Iron Ore  Shares Up 18.8%
Oceanic Iron Ore Shares Up 18.8%
Braemar Shipping Services  Stock Price Down 2.4%
Braemar Shipping Services Stock Price Down 2.4%


© 2006-2019 Ticker Report